Heart to Heart Nurses

While cancer survivorship rates continue to improve, there are CVD-related complications for patients before, during, and after cancer treatment. Guests Chelsea Kriesberg, DNP, CPNP-AC, CCRN, and Lisa Nodzon, PhD, APRN, AOCNP, describe the intersection of cancer and cardiovascular disease across the lifespan. Collaborative, team-based, and life-long care is illustrated in through a case-based discussion.

Cardiovascular risk calculator: https://ccss.stjude.org/resources/calculators/cardiovascular-risk-calculator.html

Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance. Leerink, J, de Baat, E, Feijen, E. et al. Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review. J Am Coll Cardiol CardioOnc. 2020 Sep, 2 (3) 363–378.https://doi.org/10.1016/j.jaccao.2020.08.006

Cardioprotective impacts of dexrazoxane: Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010 Oct;11(10):950-61. doi: 10.1016/S1470-2045(10)70204-7. Epub 2010 Sep 16. PMID: 20850381; PMCID: PMC3756093.

Improving quality and quantity of life for childhood cancer survivors: Ehrhardt MJ, Krull KR, Bhakta N, et al. Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century. Nat Rev Clin Oncol. 2023 Oct;20(10):678-696. doi: 10.1038/s41571-023-00802-w. Epub 2023 Jul 24. PMID: 37488230.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Caring for yourself can help you in your role of helping others. Learn strategies to nurture well-being in your daily life, and the ripple effects that can positively influence those around you, including in the workplace. Guest: Keith Jones, MA, BS

Tips for embracing joy in daily life: https://www.mayoclinichealthsystem.org/hometown-health/speaking-of-health/tips-for-embracing-joy-in-daily-life

Joy in the Workplace: The Mayo Clinic Experience: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248366/

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The prevalence of mental health issues is greater in patients with cardiovascular disease than the general population--but do you know what to look for? Guest Valerie Hoover, PhD, discusses the connection of both positive and negative psychological factors on cardiac outcomes, the importance of symptom recognition, and how regular screening for depression using a validated tool can make a significant difference for patients.

Assessment of Depression and Depressive Systems. Depression and Coronary Heart Disease (AHA 2008): https://www.ahajournals.org/doi/full/10.1161/circulationaha.108.190769

Screening and Management of Depression in Patients with CVD (ACC 2019): https://www.jacc.org/doi/abs/10.1016/j.jacc.2019.01.041

Depression Screening and Treatment Guidlines in Cardiac Patients (2022). https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.122.009338 PHQ-2: https://www.hiv.uw.edu/page/mental-health-screening/phq-2

Comparison of PHQ-2 and PHQ-9 to Predict Death or Rehospitalization in Heart Failure (Circulation, 2015): https://www.ahajournals.org/doi/full/10.1161/circheartfailure.114.001488

PHQ-2 and PHQ-9 (Heart Foundation): https://www.heartfoundation.org.au/getmedia/52e4d9ab-dbb1-47a6-bb41-94b986176910/Depression-screening-support-tool.PDF

Cardiac Distress Inventory (Australian Centre for Heart Health): https://www.australianhearthealth.org.au/resources/p/cardiac-distress-inventory

Psychosocial Factors and CVD (JACC 2020): https://www.ahajournals.org/doi/10.1161/JAHA.120.017112

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Take 1 minute to tell us what you think about this episode: pcna.net/PSVTeval

Kathryn Wood, PhD, RN, FAHA, FAAN, discusses paroxysmal supraventricular tachycardia (PSVT) and other similar episodic rapid heart rate conditions. Dr. Wood describes pathophysiology, prevalence, symptoms, and disparities related to diagnosis and treatments, and also shares helpful resources for both providers and patients.

Kathy Wood's 2015 paper with PSVT images and details: Wood K. Mechanisms and clinical manifestations of supraventricular tachycardias. Prog Cardiovasc Nurs. 1995;10(2):3-14.

Symptom research: Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol. 1997;79(2):145-149.

Symptom research: McCabe PJ, Chamberlain AM, Rhudy L, DeVon HA. Symptom Representation and Treatment-Seeking Prior to Diagnosis of Atrial Fibrillation. West J Nurs Res. 2016;38(2):200-215.

Symptom research: McCabe PJ, Rhudy LM, Chamberlain AM, DeVon HA. Fatigue, dyspnea, and intermittent symptoms are associated with treatment-seeking delay for symptoms of atrial fibrillation before diagnosis. Eur J Cardiovasc Nurs. 2016;15(6):459-468.

Symptom research: McCabe PJ, Rhudy LM, DeVon HA. Patients' experiences from symptom onset to initial treatment for atrial fibrillation. J Clin Nurs. 2015;24(5-6):786-796.

Symptom research: Streur M, Ratcliffe SJ, Callans D, Shoemaker MB, Riegel B. Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis. Eur J Cardiovasc Nurs. 2018;17(8):707-716.

Disparities: Gleason KT, Nazarian S, Dennison Himmelfarb CR. Atrial Fibrillation Symptoms and Sex, Race, and Psychological Distress: A Literature Review. J Cardiovasc Nurs. 2018;33(2):137-143.

Patient preferences in AFib education: Lane DA, Aguinaga L, Blomström-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management (EHRA, HRS, APHRS, SOLEACE consensus document). Europace. 2015;17(12):1747-1769. DOI: 10.1093/europace/euv233

ESC Guidelines: Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.

AHA My AFib Experience: https://supportnetwork.heart.org/s/myafibmain

StopAFib.org

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

[CE contact hours--see below.]: Guest Cindy Lamendola, MSN, NP, FAHA, FPCNA, describes the impacts of elevated Lp(a) on the body. Current clinical trials, and the necessity of including diverse participants are described, as well as the importance of keeping Lp(a) front of mind no matter our role as healthcare professionals.

CE LINK: https://pcna.net/online-course/ce-podcast-were-all-responsible-for-lpa

Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review: Duarte Lau F, et al. JAMA Cardiol. 2022. PMID: 35583875 Review

Lipoprotein(a) and LDL-C: The Relevance of Equivalence: Journal of the American College of Cardiology [0735-1097] Morris yr:2022 vol:80 iss:21 pg:2011 -2013

Equivalent Impact of Elevated Lp(a) and FH in Patients with ASCVD: https://www.jacc.org/doi/10.1016/j.jacc.2022.09.021

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.